Abstract
A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1072-1074 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 52 |
| Issue number | 5 |
| DOIs | |
| State | Published - Mar 23 1999 |
ASJC Scopus subject areas
- Clinical Neurology
Fingerprint Dive into the research topics of 'A safety and pharmacokinetic study of intravenous natalizumab in patients with MS'. Together they form a unique fingerprint.
Cite this
Sheremata, W. A., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J., & Koller, M. (1999). A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology, 52(5), 1072-1074. https://doi.org/10.1212/wnl.52.5.1072